nach oben

Osteoporosis International

Erschienen in:

31.08.2019 | Concise Clinical Review

Lessons learned with Bone Health TeleECHO: making treatment decisions when guidelines conflict

verfasst von: M. S. Rothman, T. P. Olenginski, I. Stanciu, K. Krohn, E. M. Lewiecki

Erschienen in: Osteoporosis International | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Clinical practice guidelines provide helpful information for managing patients with metabolic bone disease. Good guidelines are based on the best available medical evidence; however, guidelines from different societies can conflict. Additionally, it is not possible for a guideline to anticipate the vast variability of circumstances, comorbidities, previous medical experiences, cultural differences, and preferences in real-world patients. Bone Health TeleECHO is a strategy for sharing knowledge on the care of patients with skeletal diseases through ongoing interactive videoconferences. We report three cases based on those presented at Bone Health TeleECHO, where, through discussion, treatment outside of commonly used guidelines was ultimately recommended. Guidelines developed by different organizations may provide “evidence-based” or “informed” recommendations which do not account for the variability of clinical circumstances encountered in the care of individual patients. This highlights the importance of Bone Health TeleECHO, where healthcare professionals can share knowledge, individualize treatment decisions, and improve patient care.

Learning objectives

At the end of this activity participants should be able to:

• Distinguish between the onset and off of bisphosphonates versus other medications used in the prevention and treatment of osteoporosis and how this affects choice of a “drug holiday.”

• Understand the limitations of clinical practices guidelines in the care of an individual patient and how interactive video conferencing can assist with decision making.

• Recognize that patients treated with glucocorticoids at high risk for fracture can benefit from more aggressive interventions for osteoporosis.

Lewiecki EM, Boyle JF, Arora S, Bouchonville MF 2nd, Chafey DH (2017) Telementoring: a novel approach to reducing the osteoporosis treatment gap. Osteoporos Int 28(1):407–411. https://doi.org/10.1007/s00198-016-3708-2 CrossRefPubMed

Lewiecki EM, Bouchonville MF 2nd, Chafey DH, Bankhurst A, Arora S (2016) Bone Health ECHO: telementoring to improve osteoporosis care. Womens Health (Lond Engl) 12(1):79–81. https://doi.org/10.2217/whe.15.97 CrossRef

Lewiecki EM, Rochelle R (2019) Project ECHO: telehealth to expand capacity to deliver best practice medical care. Rheum Dis Clin North Am 45(2):303–314. https://doi.org/10.1016/j.rdc.2019.01.003 CrossRefPubMed

Khosla S, Cauley JA, Compston J et al (2017) Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res 32(3):424–430. https://doi.org/10.1002/jbmr.3074 CrossRefPubMed

Lewiecki EM, Rochelle R, Bouchonville MF 2nd, Chafey DH, Olenginski TP, Arora S (2017) Leveraging scarce resources with Bone Health TeleECHO to improve the care of osteoporosis. J Endocr Soc 1(12):1428–1434. https://doi.org/10.1210/js.2017-00361 CrossRefPubMedPubMedCentral

Arora S, Thornton K, Murata G et al (2011) Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 364(23):2199–2207. https://doi.org/10.1056/NEJMoa1009370 CrossRefPubMed

Project ECHO at University of New Mexico School of Medicine. ECHO Hubs: global. 2019. https://echo.unm.edu/locations/global. Accessed 25 April 2019

Cosman F, de Beur SJ, LeBoff MS et al (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359–2381. https://doi.org/10.1007/s00198-014-2794-2 CrossRefPubMedPubMedCentral

Santen RJ, Allred DC, Ardoin SP et al (2010) Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 95(7 Suppl 1):s1–s66. https://doi.org/10.1210/jc.2009-2509 CrossRefPubMedPubMedCentral

10.

Stuenkel CA, Davis SR, Gompel A et al (2015) Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100(11):3975–4011. https://doi.org/10.1210/jc.2015-2236 CrossRefPubMed

11.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137(11):875–883CrossRef

12.

Wasnich RD, Bagger YZ, Hosking DJ, McClung MR, Wu M, Mantz AM, Yates JJ, Ross PD, Alexandersen P, Ravn P, Christiansen C, Santora AC II (2004) Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 11(6 Pt 1):622–630CrossRef

13.

Castelo-Branco C, Davila J, Perello MF et al (2014) Long-term effect of hormone therapy on bone in early menopause: vertebral fractures after 20 years. Climacteric 17(4):336–341. https://doi.org/10.3109/13697137.2013.871511 CrossRefPubMed

14.

Yates J, Barrett-Connor E, Barlas S, Chen YT, Miller PD, Siris ES (2004) Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 103(3):440–446. https://doi.org/10.1097/01.AOG.0000114986.14806.37 CrossRefPubMed

15.

Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN (2011) Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 18(11):1172–1177. https://doi.org/10.1097/gme.0b013e31821b01c7 CrossRefPubMedPubMedCentral

16.

Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 310(13):1353–1368. https://doi.org/10.1001/jama.2013.278040 CrossRefPubMed

17.

Watts NB, Cauley JA, Jackson RD et al (2017) No increase in fractures after stopping hormone therapy: results from the Women’s Health Initiative. J Clin Endocrinol Metab 102(1):302–308. https://doi.org/10.1210/jc.2016-3270 CrossRefPubMed

18.

Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab 104(5):1595–1622. https://doi.org/10.1210/jc.2019-00221 CrossRefPubMed

19.

Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346(9):653–661. https://doi.org/10.1056/NEJMoa011807 CrossRefPubMed

20.

Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM (2005) Fracture Intervention Trial Research G. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 80(3):343–349. https://doi.org/10.4065/80.3.343 CrossRefPubMed

21.

Qaseem A, Forciea MA, McLean RM, Denberg TD (2017) Clinical Guidelines Committee of the American College of P. treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166(11):818–839. https://doi.org/10.7326/M15-1361 CrossRefPubMed

22.

Miller PD (2014) Chronic kidney disease and osteoporosis: evaluation and management. Bonekey Rep 3:542. https://doi.org/10.1038/bonekey.2014.37 CrossRefPubMedPubMedCentral

23.

Schwartz AV (2016) Epidemiology of fractures in type 2 diabetes. Bone 82:2–8. https://doi.org/10.1016/j.bone.2015.05.032 CrossRefPubMed

24.

Andersen BN, Johansen PB, Abrahamsen B (2016) Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol 28(4):420–425. https://doi.org/10.1097/BOR.0000000000000291 CrossRefPubMed

25.

Licata A (2009) Bone density vs bone quality: what’s a clinician to do? Cleve Clin J Med 76(6):331–336. https://doi.org/10.3949/ccjm.76a.08041 CrossRefPubMed

26.

Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. https://doi.org/10.1056/NEJMoa0809493 CrossRefPubMed

27.

Eastell R, Christiansen C, Grauer A et al (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26(3):530–537. https://doi.org/10.1002/jbmr.251 CrossRefPubMed

28.

Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32(6):1291–1296. https://doi.org/10.1002/jbmr.3110 CrossRefPubMed

29.

Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513–523. https://doi.org/10.1016/S2213-8587(17)30138-9 CrossRefPubMed

30.

Watts NB, Brown JP, Papapoulos S et al (2017) Safety observations with 3 years of denosumab exposure: comparison between subjects who received denosumab during the randomized FREEDOM trial and subjects who crossed over to denosumab during the FREEDOM extension. J Bone Miner Res 32(7):1481–1485. https://doi.org/10.1002/jbmr.3119 CrossRefPubMed

31.

Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386(9999):1147–1155. https://doi.org/10.1016/S0140-6736(15)61120-5 CrossRefPubMedPubMedCentral

32.

Miller PD, Hattersley G, Lau E et al (2019) Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial. Bone 120:137–140. https://doi.org/10.1016/j.bone.2018.10.015 CrossRefPubMed

33.

Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722–733. https://doi.org/10.1001/jama.2016.11136 CrossRefPubMed

34.

Buckley L, Guyatt G, Fink HA et al (2017) 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 69(8):1095–1110. https://doi.org/10.1002/acr.23279 CrossRef

35.

Compston J (2018) Glucocorticoid-induced osteoporosis: an update. Endocrine 61(1):7–16. https://doi.org/10.1007/s12020-018-1588-2 CrossRefPubMedPubMedCentral

36.

Lane NE (2019) Glucocorticoid-induced osteoporosis: new insights into the pathophysiology and treatments. Curr Osteoporos Rep 17(1):1–7. https://doi.org/10.1007/s11914-019-00498-x CrossRefPubMedPubMedCentral

37.

Johansson H, Siggeirsdottir K, Harvey NC et al (2017) Imminent risk of fracture after fracture. Osteoporos Int 28(3):775–780. https://doi.org/10.1007/s00198-016-3868-0 CrossRefPubMed

38.

Saag KG, Shane E, Boonen S et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357(20):2028–2039. https://doi.org/10.1056/NEJMoa071408 CrossRefPubMed

39.

Saag KG, Zanchetta JR, Devogelaer JP et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60(11):3346–3355. https://doi.org/10.1002/art.24879 CrossRefPubMed

40.

Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441. https://doi.org/10.1056/NEJM200105103441904 CrossRefPubMed

41.

Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349(13):1216–1226. https://doi.org/10.1056/NEJMoa035725 CrossRefPubMed

42.

Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32(2):198–202. https://doi.org/10.1002/jbmr.3051 CrossRefPubMed

43.

Adami G, Saag KG (2019) Glucocorticoid-induced Osteoporosis: 2019 concise clinical review. Osteoporos Int 30:1145–1156

44.

Rossini M, Adami S, Bertoldo F et al (2016) Guidelines for the diagnosis, prevention, and management of osteoporosis. Reumatismo 68:1–39. https://doi.org/10.4081/reumatismo.2016.870

45.

Leder BZ, Tsai JN, Jiang LA, Lee H (2017) Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-Follow-up). Bone 98:54–58. https://doi.org/10.1016/j.bone.2017.03.006 CrossRefPubMed

Titel: Lessons learned with Bone Health TeleECHO: making treatment decisions when guidelines conflict
verfasst von: M. S. Rothman
T. P. Olenginski
I. Stanciu
K. Krohn
E. M. Lewiecki
Publikationsdatum: 31.08.2019
Verlag: Springer London
Erschienen in: Osteoporosis International / Ausgabe 12/2019
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-019-05147-8

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

25.04.2024 | Hypertonie | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Lessons learned with Bone Health TeleECHO: making treatment decisions when guidelines conflict

Abstract

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2019

Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy—a long-term radiological follow-up

A study of dynamic contrast-enhanced MR imaging features and influence factors of pelvic bone marrow in adult females

Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure

Rapid suppression of bone formation marker in response to sleep restriction and circadian disruption in men

A bone resorption marker as predictor of rate of change in femoral neck size and strength during the menopause transition

The association between sarcopenia and osteoporotic vertebral compression refractures

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Orthopädie und Unfallchirurgie